secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2026-04-06T23:59:59+00:00
Accession:  0001193125-26-142904
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine to acquire Soleno Therapeutics for $53.00 per share in cash
----------------------------------------------------------------------

- Tender offer for all Soleno shares at $53.00 cash each; no financing condition.
- Offer requires >50% shares tendered, HSR clearance, no material adverse effect.
- Termination fees: Soleno pays $95.25M for superior proposal; Neurocrine pays $141.5M for antitrust failure.
- Soleno board recommends tender; CEO and former CFO (1.01% combined) signed support agreements.
- Deal structured as tender offer followed by merger under Section 251(h) of DGCL.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000119312526142904/0001193125-26-142904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000119312526142904/d110123d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-142904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer